This patient has severe hyperkalemia with significant ECG changes (peaked T waves, PR prolongation, QRS widening), which indicate cardiac membrane instability and a high risk of life-threatening arrhythmias. The most important first step is to stabilize the cardiac membrane. Intravenous calcium gluconate (or calcium chloride) is administered for this purpose. It does not lower the serum potassium level but directly antagonizes the toxic effects of hyperkalemia on the myocyte cell membrane, preventing arrhythmias. After membrane stabilization, therapies to shift potassium into cells (insulin/glucose, albuterol, sodium bicarbonate) and to remove potassium from the body (diuretics, cation exchange resins, hemodialysis) can be initiated.

This patient has multiple risk factors for hyperkalemia, including chronic kidney disease and the use of an ACE inhibitor (lisinopril). The most likely precipitant for her acute worsening is the recent addition of spironolactone. Spironolactone is a potassium-sparing diuretic that acts as an aldosterone antagonist. Aldosterone normally promotes potassium excretion; by blocking its effect, spironolactone can cause significant potassium retention. The combination of an ACE inhibitor (which also increases potassium by reducing aldosterone production) and spironolactone in a patient with underlying CKD is a well-known cause of severe hyperkalemia. Furosemide is a loop diuretic that causes potassium wasting.

This patient presents with hypertension, hypokalemia, and metabolic alkalosis. The high urine chloride (>20 mEq/L) suggests a saline-unresponsive cause. The combination of suppressed renin and elevated aldosterone is diagnostic for primary hyperaldosteronism (e.g., from an adrenal adenoma). Aldosterone promotes sodium reabsorption and potassium/hydrogen ion excretion in the distal tubule, leading to hypertension, hypokalemia, and metabolic alkalosis. Renovascular hypertension would cause secondary hyperaldosteronism with elevated renin. Thiazide use and Bartter syndrome cause hypokalemia and alkalosis but are typically associated with normal or low blood pressure.

This patient has chronic respiratory acidosis due to CO₂ retention from emphysema. The kidneys compensate by retaining bicarbonate to normalize the pH. The rule of thumb for chronic respiratory acidosis is that for every 10 mm Hg increase in pCO₂ above 40, the bicarbonate increases by 3-4 mEq/L. The patient's pCO₂ is 25 mm Hg above normal (65 - 40 = 25). The expected increase in bicarbonate would be 2.5 * (3 to 4) = 7.5 to 10 mEq/L. Adding this to a normal bicarbonate of 24 mEq/L gives an expected range of 31.5 to 34 mEq/L. The value of 34 mEq/L falls within this range and is consistent with full renal compensation.

Hypomagnesemia is a common finding in patients with alcohol use disorder and is a frequent cause of refractory hypokalemia. Magnesium is a crucial cofactor for the Na-K-ATPase pump, which maintains the intracellular potassium concentration. Additionally, magnesium blocks the renal outer medullary potassium (ROMK) channels in the collecting duct, preventing potassium secretion. In a state of hypomagnesemia, this inhibition is lost, leading to continuous renal potassium wasting. Therefore, in a patient with refractory hypokalemia, especially with risk factors like alcoholism, magnesium levels must be checked and repleted before potassium can be effectively corrected.

This patient's presentation is classic for the syndrome of inappropriate antidiuretic hormone secretion (SIADH), which is a common paraneoplastic syndrome associated with small cell lung cancer. The diagnosis is supported by euvolemic hyponatremia, low serum osmolality, inappropriately concentrated urine (urine osmolality > 100 mOsm/kg), and elevated urine sodium (>40 mEq/L). The patient is asymptomatic or has mild symptoms (fatigue, nausea). The first-line treatment for mild to moderate SIADH is fluid restriction. This reduces the free water intake, allowing the serum sodium to rise gradually. 0.9% saline can worsen hyponatremia in SIADH. 3% saline is reserved for severe symptoms like seizures. Desmopressin is used to treat central diabetes insipidus.

The patient has an acidosis (pH < 7.35) with a high pCO₂ (70 mm Hg), indicating a respiratory acidosis. To determine if it is acute, chronic, or acute-on-chronic, we assess the bicarbonate level. In acute respiratory acidosis, bicarbonate increases by about 1 mEq/L for every 10 mm Hg increase in pCO₂ above 40. In chronic respiratory acidosis, it increases by 3-4 mEq/L for every 10 mm Hg increase. This patient's pCO₂ is 30 mm Hg above normal. An acute process would result in a bicarbonate of ~24 + 3 = 27 mEq/L. A chronic process would result in a bicarbonate of ~24 + (3 * 3.5) = ~34.5 mEq/L. The patient's bicarbonate of 28 mEq/L is higher than expected for a purely acute process but lower than expected for full compensation, indicating an acute exacerbation superimposed on his chronic CO₂ retention (acute-on-chronic respiratory acidosis).

Intravenous potassium chloride is caustic to peripheral veins and can cause significant pain, phlebitis, and tissue necrosis if it extravasates. To minimize these risks, the rate of infusion through a peripheral line should generally not exceed 10 mEq/hour. The concentration should also be limited, typically to no more than 40 mEq/L. Higher rates (e.g., 20 mEq/hour or more) require a central venous catheter and continuous cardiac monitoring due to the risk of inducing life-threatening hyperkalemia and arrhythmias.

This patient's presentation of hypernatremia, polyuria, and inappropriately dilute urine following a head injury is highly suggestive of central diabetes insipidus (DI), caused by decreased ADH secretion. A water deprivation test is the classic diagnostic test but may be dangerous in a critically ill patient with high urine output. A more practical approach in this setting is to administer a therapeutic and diagnostic trial of desmopressin (an ADH analog). In central DI, administration of desmopressin will lead to a rapid decrease in urine output and an increase in urine osmolality, confirming the diagnosis. In nephrogenic DI, there would be no significant response.

This patient has a normal anion gap metabolic acidosis (NAGMA) calculated as 140 - (112 + 16) = 12. The presence of hypokalemia and NAGMA suggests either diarrhea or a renal tubular acidosis (RTA). The inappropriately high urine pH (>5.5) in the setting of systemic acidosis is the hallmark of Type 1 (distal) RTA, which is caused by impaired H⁺ secretion in the distal tubule. Sjögren syndrome is a known cause of Type 1 RTA. Type 2 RTA involves impaired bicarbonate reabsorption and the urine can be acidified. Type 4 RTA is associated with hyperkalemia. Diarrhea would cause a NAGMA with hypokalemia, but the urine would be appropriately acidic (pH <5.5).